NASDAQ:PRTOProteon Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Proteon Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $27.42 -1.43 (-4.96 %) (As of 07/10/2020 04:00 PM ET) Add Compare Share Today's Range$26.65Now: $27.42▼$28.7450-Day Range$22.52MA: $36.79▼$60.7052-Week Range$0.22Now: $27.42▼$3.94Volume21,400 shsAverage Volume1.11 million shsMarket Capitalization$608.15 millionP/E RatioN/ADividend YieldN/ABeta0.6 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Proteon Therapeutics. Previous Next 2.6 Community Rank Outperform VotesProteon Therapeutics has received 272 “outperform” votes. (Add your “outperform” vote.)Underperform VotesProteon Therapeutics has received 243 “underperform” votes. (Add your “underperform” vote.)Community SentimentProteon Therapeutics has received 52.82% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Proteon Therapeutics and other stocks. Vote “Outperform” if you believe PRTO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PRTO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldProteon Therapeutics does not currently pay a dividend.Dividend GrowthProteon Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Proteon Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders45.70% of the stock of Proteon Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 23.03% of the stock of Proteon Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Proteon Therapeutics are expected to grow in the coming year, from ($0.78) to ($0.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Proteon Therapeutics is -23.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Proteon Therapeutics is -23.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.85 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRTO Previous Symbol CUSIPN/A CIK1359931 Webwww.proteontherapeutics.com Phone781-890-0102Debt Debt-to-Equity RatioN/A Current Ratio5.98 Quick Ratio5.98Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.06) per share Price / Book-457.00Profitability EPS (Most Recent Fiscal Year)($1.15) Net Income$-20,730,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-118.68%Miscellaneous Employees17 Outstanding Shares22,179,000Market Cap$608.15 million Next Earnings Date8/5/2020 (Estimated) OptionableNot Optionable NASDAQ:PRTO Rates by TradingView Receive PRTO News and Ratings via Email Sign-up to receive the latest news and ratings for PRTO and its competitors with MarketBeat's FREE daily newsletter. Proteon Therapeutics (NASDAQ:PRTO) Frequently Asked Questions How has Proteon Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Proteon Therapeutics' stock was trading at $24.20 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PRTO stock has increased by 13.3% and is now trading at $27.42. View which stocks have been most impacted by Coronavirus. When is Proteon Therapeutics' next earnings date? Proteon Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Proteon Therapeutics. How were Proteon Therapeutics' earnings last quarter? Proteon Therapeutics Inc (NASDAQ:PRTO) issued its quarterly earnings data on Thursday, October, 31st. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.09) by $0.01. View Proteon Therapeutics' earnings history. Has Proteon Therapeutics been receiving favorable news coverage? Headlines about PRTO stock have trended very negative on Sunday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Proteon Therapeutics earned a news sentiment score of -3.8 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Proteon Therapeutics. Who are some of Proteon Therapeutics' key competitors? Some companies that are related to Proteon Therapeutics include Twist Bioscience (TWST), Immunovant (IMVT), Alector (ALEC), Editas Medicine (EDIT), Bill.com (RVMD), Sorrento Therapeutics (SRNE), SpringWorks Therapeutics (SWTX), Adverum Biotechnologies (ADVM), Mesoblast (MESO), Sangamo Therapeutics (SGMO), Legend Biotech (PCVX), Regenxbio (RGNX), Beam Therapeutics (BEAM), Nantkwest (NK) and Cortexyme (CRTX). View all competitors. What other stocks do shareholders of Proteon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Proteon Therapeutics investors own include Celgene (CELG), SCYNEXIS (SCYX), Sierra Oncology (SRRA), Agile Therapeutics (AGRX), Biocept (BIOC), ImmunoGen (IMGN), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP) and TherapeuticsMD (TXMD). Who are Proteon Therapeutics' key executives? Proteon Therapeutics' management team includes the following people: Mr. Timothy P. Noyes, Pres, CEO & Director (Age 57)Mr. George A. Eldridge, Sr. VP, CFO, Treasurer & Assistant Sec. (Age 56)Dr. Steven Keith Burke, Sr. VP & Chief Medical Officer (Age 58)Mr. Matthew P. Kowalsky, VP of Legal & Sec. (Age 46)Mr. Bradley J. Hartman, VP of People (Age 38) What is Proteon Therapeutics' stock symbol? Proteon Therapeutics trades on the NASDAQ under the ticker symbol "PRTO." How do I buy shares of Proteon Therapeutics? Shares of PRTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Proteon Therapeutics' stock price today? One share of PRTO stock can currently be purchased for approximately $27.42. How big of a company is Proteon Therapeutics? Proteon Therapeutics has a market capitalization of $608.15 million. The biopharmaceutical company earns $-20,730,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis. Proteon Therapeutics employs 17 workers across the globe. What is Proteon Therapeutics' official website? The official website for Proteon Therapeutics is www.proteontherapeutics.com. How can I contact Proteon Therapeutics? Proteon Therapeutics' mailing address is 200 WEST STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 781-890-0102 or via email at [email protected] This page was last updated on 7/12/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
